BTIG Starts Rite-Aid (RAD) at Buy, Sees a Near Double
Tweet
Share
E-mailGet Alerts RAD Hot Sheet
Price: $0.65 --0%
Rating Summary:
5 Buy, 7 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
5 Buy, 7 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
BTIG initiates coverage on Rite-Aid (NYSE: RAD) with a Buy. PT $2.25.
"We believe that the retail market in the US for branded and generic drugs has positive long term fundamentals, incremental prospects for steady growth and the ability to withstand the worst effects of economic volatility," the analyst said. "We believe that Rite Aid equity is attractive because it is the name most highly levered to these value-creating factors and stands to benefit the most from any multiple expansion or free cash flow growth."
While Rite-Aid's debt structure is complex, it is "manageable" and gives equity investors the benefit of leverage.
For an analyst ratings summary and ratings history on Rite-Aid click here. For more ratings news on Rite-Aid click here.
Shares of Rite-Aid closed at $1.16 yesterday.
"We believe that the retail market in the US for branded and generic drugs has positive long term fundamentals, incremental prospects for steady growth and the ability to withstand the worst effects of economic volatility," the analyst said. "We believe that Rite Aid equity is attractive because it is the name most highly levered to these value-creating factors and stands to benefit the most from any multiple expansion or free cash flow growth."
While Rite-Aid's debt structure is complex, it is "manageable" and gives equity investors the benefit of leverage.
For an analyst ratings summary and ratings history on Rite-Aid click here. For more ratings news on Rite-Aid click here.
Shares of Rite-Aid closed at $1.16 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Starts SpyGlass Pharma (SGP) at Outperform
- Raymond James Starts Polaryx Therapeutics (PLYX) at Strong Buy
- Leerink Starts Freenome Inc. (FRNM) at Outperform
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
